JZJakub Michal Zimodro

Jakub Michal Zimodro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakub Michal Zimodro has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reclassification of Clinical Familial Hypercholesterolemia Diagnoses After Adjustment of LDL-C for Lipoprotein(a) Cholesterol: A Systematic Review and Meta-Analysis

    by Grzegorz Procyk, Adam Sukiennik, Jakub Michal Zimodro

    Background/Objectives: Low-density lipoprotein cholesterol (LDL-C) measurements include cholesterol carried by lipoprotein(a) [Lp(a)], which may influence the clinical classification of familial hypercholesterolemia (FH). We aimed to systematically review the available evidence and estimate the pooled proportion of individuals reclassified to a lower FH diagnostic category after correction of LDL-C for estimated Lp(a)-cholesterol. Methods: Embase, PubMed, and Scopus were searched from inception through 9 October 2026. We included observational studies with cross-sectional analyses of adults aged ≥18 years evaluated for suspected FH using the Dutch Lipid Clinic Network (DLCN) criteria before and after LDL-C correction for Lp(a)-cholesterol. Lp(a)-cholesterol was estimated as 30% of Lp(a) mass. The primary endpoint was reclassification to a lower DLCN diagnostic category among participants with possible, probable, or definite FH at baseline. Random-effects models were used to estimate pooled proportions. Risk of bias was assessed using the JBI critical appraisal tool for cross-sectional studies. Results: Four studies comprising 2970 individuals were included. The primary analysis included 2793 participants with possible, probable, or definite FH at baseline. After LDL-C correction for estimated Lp(a)-cholesterol, 19.8% (95% CI, 15.9–24.5) were reclassified to a lower DLCN diagnostic category. Conclusions: Correction of LDL-C for estimated Lp(a)-cholesterol resulted in downward DLCN reclassification in approximately one in five adults with at least possible FH from selected referral populations. The clinical utility of this adjustment, including its consequences for genetic testing and missed FH diagnoses, needs to be investigated.

  • One‐Year Outcomes of High‐Risk Percutaneous Coronary Interventions With Versus Without Mechanical Circulatory Support: Propensity Score‐Matched Analysis

    by Aleksandra Gąsecka, Arkadiusz Pietrasik, Tomasz Pawłowski, Jakub Michal Zimodro, Daniel Cieśla, Jerzy Sacha, Marek Grygier, Janusz Kochman, Mateusz Tajstra, Krzysztof Dyrbuś, et al.

    Background: Impella is increasingly used as mechanical circulatory support (MCS) during high‐risk percutaneous coronary interventions (HR‐PCI). Registry‐based data provide insights into the efficacy and safety of Impella‐assisted HR‐PCI. Aims: We aimed to evaluate 1‐year outcomes of Impella‐assisted HR‐PCI compared to HR‐PCI without MCS. Methods: One hundred and thirty‐eight patients undergoing Impella‐assisted PCI, included in the IMPELLA‐PL registry, were propensity score‐matched with controls from the retrospective CardioSilesia registry who underwent HR‐PCI without MCS. Study endpoints included 1‐year post‐discharge all‐cause mortality, myocardial infarction (MI), stroke, rehospitalization for heart failure (HF), and repeat coronary revascularization. Results: Clinical and angiographic characteristics were comparable in both groups, with higher rates of dyslipidemia (78.3% vs. 37.7%, p < 0.001), chronic kidney disease (39.9% vs. 16.7%, p < 0.001), and peripheral artery disease (34.1% vs. 8.0%, p < 0.001) in the IMPELLA‐PL cohort. Intravascular ultrasound was more frequently used in the Impella‐supported patients (44.2% vs. 25.4%, p = 0.002), while staged revascularization was more common among controls (30.4% vs. 15.9%, p = 0.007). At 1 year, rates of post‐discharge all‐cause mortality, stroke, and repeat coronary revascularization were similar in both groups. MI was less frequent in the IMPELLA‐PL cohort (1.4% vs. 10.9%, p = 0.003), alongside a trend toward lower incidence of rehospitalizations for HF (9.4% vs. 18.1%, p = 0.055). Conclusions: Despite an unfavorable cardiovascular risk profile, patients who underwent Impella‐assisted HR‐PCI had similar 1‐year post‐discharge survival, with a lower rate of MI, compared to propensity score‐matched controls who underwent HR‐PCI without MCS. Impella may improve HR‐PCI outcomes in selected patients, but further randomized controlled trials are required to confirm this finding.

  • Bempedoic acid in a high-risk primary-prevention patient unable to take statins: a case-based approach

    by Natalia Barańska, Jakub M. Zimodro, Renata Główczyńska, Marcin Grabowski, Joanna Rogozik

  • Open Access

    Bempedoic Acid: From Guidelines to the Real World

    by Jakub Michal Zimodro, Ioanna Gouni-Berthold

    Zimodro JM, et al. J Lipid Atheroscler. 2026 Sep;15(3):381-398. https://doi.org/10.12997/jla.2026.15.3.381

  • Open Access

    Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines

    by Tomasz Saniewski, Jakub Michal Zimodro, Grzegorz Procyk, Olivia Wasilewska, Bartosz Mroczyk, Michał Lis, Maciej Banach, Aleksandra Gąsecka

    Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.


  • Open Access

    Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review

    by Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold

    Hypertriglyceridemia (HTG) is associated with a residual risk of atherosclerotic cardiovascular disease. Extremely elevated triglyceride (TG) concentrations, particularly due to familial chylomicronemia syndrome (FCS), pose a risk for acute pancreatitis. Standard therapies with statins, fibrates, omega-3 fatty acids, and niacin may be insufficient to reduce elevated TG levels and improve clinical outcomes in patients with HTG. Novel antisense oligonucleotides and small interfering ribonucleic acids target the key modulators of TG-rich lipoprotein catabolism. Among apolipoprotein C-III (apoC-III) inhibitors, olezarsen and plozasiran appear to be safer alternatives for volanesorsen regarding the risk of drug-induced thrombocytopenia in patients with FCS or severe HTG. After the failure of vupanorsen, a new angiopoietin-like protein 3 (ANGPTL3) inhibitor, zodasiran, demonstrated the potential to decrease TG levels in patients with moderate HTG. Meanwhile, the fibroblast growth factor 21 (FGF21) analog, pegozafermin, became another candidate for the treatment of severe HTG. This comprehensive review outlines pharmacological targets in TG-rich lipoprotein metabolism, discusses international guidelines, and summarizes the latest evidence from clinical trials to provide insight into the current and emerging treatment options for primary HTG.


  • Open Access

    Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review

    by Jakub Michal Zimodro, Magda Mucha, Heiner K. Berthold, Ioanna Gouni-Berthold

    Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a), and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses the diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.


  • Open Access

    Sex aspects in lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy: A comprehensive review

    by Jakub Michal Zimodro, Magda Mucha, Heiner K. Berthold, Ioanna Gouni-Berthold

    Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a) and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT’s target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.


  • Open Access

    Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction

    by Jakub Michal Zimodro, Aleksandra Gąsecka, Piotr Arski, Jonas Schwarz, Maciej Banach, Ioanna Gouni-Berthold


  • Open Access

    AngioScore: An artificial intelligence tool to assess coronary artery lesions

    by Ewelina Blazejowska, Jakub Michal Zimodro, Tomasz Figatowski, Adam Brzeski, Tomasz Dziubich, Jaroslaw Parzuchowski, Aleksandra Gasecka, Radoslaw Targonski